Humana Inc.
292.67-2.13 (-0.72%)
Oct 29, 4:00:02 PM EDT · NYSE · HUM · USD
Key Stats
Market Cap
35.20BP/E (TTM)
22.43Basic EPS (TTM)
13.05Dividend Yield
0.01%Recent Filings
8-K
Humana's 2026 Star Ratings preview
Humana disclosed preliminary 2026 Medicare Advantage Star Ratings on October 2, 2025, showing 20% of members in 4-star-plus plans with an average of 3.61, matching 2025 levels but up to 14% in 4.5-star plans from 3%. While not ideal, these align with multiyear financial plans, affirming no changes to 2025-2028 earnings outlook. The company eyes stronger 2027 results through operational shifts. Humana sticks to 2025 guidance of ~$17.00 adjusted EPS.
8-K
Humana reaffirms 2025 EPS guidance
Humana reaffirmed its FY 2025 guidance during upcoming investor meetings from September 1 to 30, projecting approximately $13.77 in GAAP diluted EPS and $17.00 in adjusted EPS, consistent with July 30 disclosures. The adjusted figure reconciles from GAAP by adding back amortization, put/call adjustments, value initiatives, and impairments, netting a $3.23 uplift after taxes. Humana won't comment on 2026 Medicare Advantage Star Ratings until CMS releases final data in October. Forward-looking guidance carries risks outlined in SEC filings.
8-K
Humana raises 2025 EPS guidance
Humana reported Q2 2025 GAAP EPS of $4.51 and adjusted EPS of $6.27, with insurance segment benefit ratio at 89.9%, aligning with expectations amid Medicare Advantage membership declines offset by strong CenterWell growth. The company raised full-year 2025 adjusted EPS guidance to approximately $17.00 from $16.25 and revenues to at least $128 billion, while trimming individual Medicare Advantage membership drop to up to 500,000 members, prioritizing sustainable value through plan exits. CenterWell Primary Care eyes 50,000-70,000 net patient additions, but Star Ratings declines risk 2026 bonuses.
10-Q
Q2 FY2025 results
Humana's Q2 FY2025 results showed premiums climbing 9.1% year-over-year to $30.7B, fueled by higher Medicare subsidies from the Inflation Reduction Act and growth in state-based contracts, though individual Medicare Advantage membership dipped 6.9% amid plan exits. Operating income held steady at $1.1B despite a 70 basis point rise in the benefit ratio to 89.7%, driven by business mix shifts and investments in outcomes, while value creation initiatives trimmed costs. Cash swelled to $4.0B, up from $2.2B at year-end, with free cash flow of $1.4B (derived) supporting $100M in share repurchases and $214M in dividends; total debt stood at $12.6B, bolstered by a $5.0B revolving facility. Yet regulatory pressures from CMS's RADV audits loom large.
8-K
Humana reaffirms 2025 EPS guidance
Humana reaffirmed its FY 2025 guidance during senior management meetings with investors from June 2 to June 30, projecting GAAP diluted EPS of approximately $14.68 and adjusted EPS of $16.25, consistent with April's outlook. The reconciliation highlights adjustments for intangibles amortization ($0.49), put/call valuations ($1.35), value initiatives ($0.20), and tax impacts (-$0.47). An Investor Conference on June 16 will detail strategic and financial progress. Forward-looking statements carry risks as noted in SEC filings.
CI
The Cigna Group
299.12-9.29
CNC
Centene Corporation
37.34+4.15
CVS
CVS Health Corporation
80.60-1.60
EHTH
eHealth, Inc.
5.46-0.19
ELV
Elevance Health, Inc.
336.36-3.04
GOCO
GoHealth, Inc.
4.07-0.25
HCA
HCA Healthcare, Inc.
468.40+1.94
MOH
Molina Healthcare Inc
160.28-2.56
NEUE
NeueHealth, Inc.
6.75+0.00
UNH
UnitedHealth Group Incorporated
355.26-12.58